
Original summary · AI-drafted, human-published · added by Library
Patrick Radden Keefe traces three generations of the Sackler family from Depression-era Brooklyn to global philanthropy, showing how a family fortune built on advertising psychiatric drugs was later used to sell OxyContin as a nearly non-addictive painkiller. He argues that the same marketing playbook, the same denial of harm, and the same insulation of the family from consequences recur across decades, turning a private pharmaceutical company into one of the central engines of America's opioid crisis.
Pick a finish date and Genius lays out the days — the plan shows today's target and keeps you honest.
Start a circle and share the code — everyone sees everyone's honest place in the book. Accountability, not leaderboards.
- Readers of investigative journalism who want a documented account of how a public health disaster was manufactured and defended - People affected by the opioid crisis, or working in addiction treatment, policy, or public health, who want the corporate backstory - Anyone curious about how wealthy families use philanthropy, secrecy, and litigation strategy to control their public reputation
The manipulative marketing techniques later used to sell OxyContin were not invented at Purdue Pharma but were perfected decades earlier by Arthur Sackler while selling Valium.
The Sacklers' decision to keep Purdue private and their finances opaque let one branch profit enormously from OxyContin while another could later claim moral distance from it.
The reputation for safety that Purdue built with MS Contin for cancer patients was transferred, without adequate justification, to a much broader population taking OxyContin for chronic pain.
Purdue's sales force was structured to reward volume and dosage escalation regardless of warning signs, making abuse and diversion a predictable outcome of the incentive design, not a surprise.
Purdue's 2007 guilty plea proved that a company could admit criminal wrongdoing in marketing OxyContin while leaving the family that owned and directed it personally untouched.
The Sackler name on museum wings and university buildings functioned for decades to obscure, not merely decorate, the family's connection to a company selling a dangerous opioid.
As litigation risk against Purdue grew after 2007, the family accelerated withdrawals from the company, moving roughly $10.7 billion out between 2008 and 2018 in a pattern that outpaced the pending legal claims.
Public pressure campaigns, led by artist Nan Goldin, succeeded in stripping the Sackler name from major museums years before any court forced the family to give up anything.
Purdue's 2019 bankruptcy filing functioned less as a response to insolvency and more as a legal strategy to secure permanent protection for the Sackler family, who never filed for bankruptcy themselves.
Purdue's 2020 criminal guilty plea proved that a corporation can be convicted of felony conduct in an epidemic that killed hundreds of thousands, while no individual Sackler faces a criminal charge.
Patrick Radden Keefe is a staff writer at The New Yorker and author of Say Nothing and Rogues. He specializes in long-form investigative journalism on crime, secrecy, and institutional power, drawing on court records, depositions, and hundreds of interviews. His 2017 Esquire article on the Sackler family's connection to Purdue Pharma became the seed for this book.